Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 5/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426612 | 0.75 | ALDH1A1 (0.51) | ACACBACACA | |
| SCHEMBL17460180 | 0.74 | SLC6A7 (0.47) | FAAH | |
| SCHEMBL17460166 | 0.74 | SCD5 (0.42) | ACACBACACA | |
| SCHEMBL425475 | 0.74 | TACR3 (0.53) | FAAHHCRTR1 | |
| SCHEMBL424684 | 0.73 | ALDH1A1 (0.45) | FAAHACACBACACA | |
| SCHEMBL427480 | 0.73 | FAAH (0.46) | USP19FAAHCES2HCRTR1 | |
| SCHEMBL19293990 | 0.72 | FAAH (0.47) | FAAH | |
| SCHEMBL425650 | 0.72 | HPGD (0.53) | — | |
| SCHEMBL425825 | 0.71 | FAAH (0.40) | USP19FAAHCES2 | |
| SCHEMBL17460173 | 0.71 | TP53 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606035-B1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA S A (PT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2606035-B1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA S A (PT) | 2017-09-06 | — | — | EP | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | USP19 188/4885FAAH 2166/4885CES2 463/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | USP19 744/4885FAAH 1/4885CES2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.